216 results about "Quercitrin" patented technology

The invention relates to the technical field of exosomes, in particular to an exosome compound preparation with a hair growing effect and a preparation method of the exosome compound preparation. Comprising 12 to 22 parts of ginsenoside Rb1, 15 to 12 parts of biotin tripeptide-15, 8 to 15 parts of diammonium glycyrrhizinate, 50 to 70 parts of fish collagen peptide, 10 to 20 parts of soybean peptide, 0.5 to 4.5 parts of SHH protein, 0.5 to 2.5 parts of SMO inhibitor, 0.5 to 1.5 parts of HhSP protein, 5 to 10 parts of N-acetyl tyrosine, 0.1 to 2 parts of hyaluronic acid, 0.1 to 1 part of melatonin, 0.1 to 1 part of quercetin, 0.1 to 1 part of kaempferol, 0.1 to 1 part of tanshinone, 0.1 to 1 part of biotin and 0.1 to 1 part of vitamin A. The compound preparation is combined with exosomes from various sources, so that the hair papilla cell function is synergistically enhanced, and the damaged hair follicle structure is repaired.

The application discloses a galactosyltransferase mutant and application thereof in preparation of flavonoid compounds, and belongs to the technical field of enzymology. The application provides a UDP-galactosyltransferase mutant, which is obtained by site-directed mutation of one amino acid in the amino acid sequence of wild-type galactosyltransferase VcUFGT into alanine (A). The effects of a series of mutants H82A, V139A, G141A, P186A, N245A, V282A and S307A are verified in the examples, the mutants can perform enzyme catalysis reaction with quercetin and UDP-galactoside as substrates, and generate flavonoid compound hyperoside, and the specific enzyme activity of the mutants is more than 1.5 times that of the wild type, thereby providing an effective application basis for biosynthesis of flavonoid compounds.

The invention belongs to the technical field of biological medicine, and particularly relates to an extracellular vesicle drug delivery system, a preparation method thereof and application of the extracellular vesicle drug delivery system in treatment of Alzheimer's disease. According to the invention, one or more of stilbene glucoside, emodin, kaempferol, resveratrol and quercetin are used for regulating and controlling the expression of miRNA (micro Ribonucleic Acid) related to the disease progress in the extracellular vesicles, and the result shows that one or more of miR-let-7c-5p, miR-486-5p, miR-132-3p, miR-160b and miR-129-5p is remarkably up-regulated, and one or more of miR-342-3p, miR-16-5p and miR-125b-5p is remarkably down-regulated. The regulated extracellular vesicles can be used for treating Alzheimer's disease, relieving Tau protein abnormal phosphorylation, reducing amyloid protein beta deposition, inhibiting microglial cell activation, protecting neuronal cells and relieving memory deficits.

Compositions that contain flavonoids such as hesperidin, quercetin, hesperetin, and rutin and methods of treating viral diseases such as coronavirus (e.g., SARS COV-2) infection, influenza virus infection, rhinovirus infection, and human metapneumovirus infection.

The application provides a composite imprinting polymer and a preparation method and application thereof, and belongs to the field of compound extraction.The composite imprinting polymer comprises a core, a shell and a shell;the core comprises Fe3O4 and SiO2 coated on the Fe3O4;the shell comprises MOF material and imprinting polymer coated on the MOF;raw materials for preparing the imprinting polymer comprise a template molecule, a functional monomer, a crosslinking agent and an initiator;the template molecule is quercetin;the functional monomer comprises two of methyl methacrylate, styrene, 4-vinylpyridine and acrylamide; and the crosslinking agent comprises ethylene glycol dimethacrylate.The material has the triple advantages of magnetic rapid separation, high specific surface area of MOF and specific recognition of molecular imprinting, and exhibits high adsorption capacity and excellent selectivity for quercetin.

The invention relates to the technical field of traditional Chinese medicines, and discloses application of an active ingredient of shiny-leaved yellowhorn leaves in preparation of a medicine for treating hyperuricemia. The xanthoceras sorbifolia leaf active ingredients comprise quercitrin, rutin and myricetin; the content of quercitrin is 0.2508 mg / g to 0.6719 mg / g, the content of rutin is 0.6707 mg / g to 1.5831 mg / g, and the content of myricetin is 0.8002 mg / g to 3.4858 mg / g. According to the invention, myricetin, quercitrin and rutin are determined as core effective substances of shiny-leaved yellowhorn leaves for treating hyperuricemia for the first time; the multi-target and multi-channel action mechanism is disclosed; meanwhile, network pharmacological analysis shows that the three components have high connectivity in a network and jointly act on key targets such as XOD, ACE, AKR1B1 and TNF, it is prompted that the three components do not act singly, but play a treatment role through multi-target and multi-channel cooperation, the traditional'single target-single drug 'thinking is changed into a'multi-component-multi-target-multi-channel' system regulation mode, and the treatment effect is improved. A new thought is provided for comprehensive treatment of the hyperuricemia.

The invention discloses oral multi-effect analgesic and anti-inflammatory gel and a preparation method thereof, and belongs to the technical field of medical gel. The gel is prepared from mussel mucin grafted hydroxypropyl chitosan, a poly (N-isopropylacrylamide)-co-acrylic acid copolymer, quercetin-zinc coordination nanoparticles, a local anesthetic compound wrapped by temperature-sensitive lipidosome, a gamma-polyglutamic acid-catechin gel matrix, aloe polysaccharide, dipotassium glycyrrhizinate, and sodium hyaluronate and potassium sorbate which can be selectively added, wherein the local anesthetic compound is prepared from the mussel mucin grafted hydroxypropyl chitosan, the poly (N-isopropylacrylamide)-co-acrylic acid copolymer, the quercetin-zinc coordination nanoparticles, the temperature-sensitive lipidosome, the gamma-polyglutamic acid-catechin gel matrix, the aloe polysaccharide and the dipotassium glycyrrhizinate. During preparation, part of the components and water are stirred to obtain a mixed solution, and then the other components are added and stirred into gel. According to the gel, the leakage rate of local anesthetics is reduced by stabilizing the liposome through the zinc ions, the quercetin adjusts the phase transition temperature of the liposome to realize preferential drug release at the pain part, the mussel mucin and the copolymer form a reversible hydrogen bond network to enhance the mucous membrane adhesive force, and the inflammatory environment triggers the gel permeation drug release, so that the gel has the advantages of multiple-effect synergy, strong adhesion and the like; the problems that existing oral gel is short in analgesia time and insufficient in anti-inflammation can be effectively solved.

The invention provides a method for treating AR negative TNBC through combination of quercetin and enzalutamide, the quercetin up-regulates the AR expression level by inhibiting a high-expression solute carrier SLC7A5, so that tumor cells which are not sensitive to enzalutamide originally obtain drug sensitivity again; the combined use of an AR antagonist enzalutamide (1-80 [mu] M) can cooperatively block an AR signal channel and significantly inhibit cell proliferation (the inhibition rate of drug combination is 70%, Plt, 0.01 higher than that of a single drug). In-vitro experiments prove that the scheme has a synergistic effect (the effect is optimal when the mass ratio is 1: 1-5: 1) in MDA-MB-231 cells, and an animal model shows that the tumor volume inhibition rate reaches 70% or above. Safety evaluation shows that the drug combination does not cause abnormity of serum biochemical indexes (ALT / AST / BUN / CREA) or damage of main organs and tissues. The invention further provides a preparation method of an oral preparation (tablets / capsules / nanoparticles) containing quercetin (50-500 mg / day) and enzalutamide (40-160 mg / day), and a new strategy is provided for reversing AR-TNBC drug resistance.

The application discloses a three-channel fluorescence sensor array based on sulfur quantum dots and a preparation method and detection application thereof. The sensor array is composed of three kinds of sulfur quantum dots, namely C-SQDs, PSS-SQDs and beta-SQDs. When target objects exist, the three kinds of sensing units generate differentiated fluorescence responses, forming a unique "fingerprint map". By using principal component analysis to analyze the response mode, the array can successfully distinguish between structurally similar baicalein, fiscetin, myricetin, quercetin and rutin in a concentration range of 8.0-56 muM. In addition, the array can also perform semi-quantitative analysis on a single flavone compound in a range of 4.0-56 muM, and the first principal component has a good linear relationship with the logarithm of the concentration of the target object.

The invention provides a heat-stress-resistant laying hen feed and a preparation method thereof. The heat-stress-resistant laying hen feed comprises the following raw materials in parts by weight: 50-60 parts of corn, 10-20 parts of soybean meal, 5-15 parts of wheat bran, 1-5 parts of vegetable oil, 5-12 parts of fish meal, 2-5 parts of beta-alanine, 2-5 parts of activated black bean powder, 2-5 parts of quercitrin, 0.2-0.5 part of multivitamins, 4-8 parts of an electrolyte poising agent and 2-3 parts of compound amino acids. The activated black bean powder is obtained by performing enzymolysis activation on black bean powder by using an aromatic amino acid decarboxylase preparation. The laying hen feed disclosed by the invention can be used for feeding laying hens in a high-temperature environment in summer, and through a unique heat stress resistant formula, the heat stress resistant capacity of the laying hens is remarkably improved, adverse effects caused by heat stress are reduced, meanwhile, the antioxidant capacity and the immune function of the laying hens are enhanced, and the growth performance and the egg laying performance of the laying hens are improved.

According to the application of the hydrogel preparation loaded with the quercetin nanoparticles to preparation of a chronic difficult-to-heal wound surface treatment material, Que-coated HZ hydrogel is obtained through physical loading of QueNPs and crosslinking of modified hyaluronic acid and Zn < 2 + >, full-stage management of wound healing can be achieved, rapid healing and tissue regeneration of the wound surface are promoted through the synergistic effect of all the components, and the healing effect of the wound surface is improved. A comprehensive treatment strategy is provided for chronic wound surfaces difficult to heal, and the Que-coated HZ hydrogel promotes transformation of macrophages from an M1 phenotype to an M2 phenotype and shows a good anti-inflammatory effect. In the early stage, the hydrogel preferentially releases Zn < 2 + > to achieve the antibacterial effect and relieve local inflammation, in the later stage, QueNps gradually releases Que to reduce ROS generation, so that the anti-oxidation and anti-inflammatory effects are achieved, wound repair is accelerated, and meanwhile the released Que can resist mitochondrial damage and improve the mitochondrial function.

The invention relates to hydroxylated polyamide-amine dendrimer integrated drug-loaded nanogel as well as a preparation method and application thereof. The drug-loaded nanogel comprises third-generation polyamide-amine dendrimer integrated nanogel modified by double bonds and high-density hydroxyl groups, MnO2 nanoparticles and quercetin, wherein the nanogel is loaded with MnO2 nanoparticles in situ, and quercetin is physically wrapped in the nanogel. The drug-loaded nanogel disclosed by the invention can enhance a blood-brain barrier penetrating effect, regulate microglial cells and neurons in a double-target manner and remodel a brain inflammation microenvironment, so that neuroinflammation and dyskinesia of a Parkinson's disease model mouse are relieved, and the curative effect of the Parkinson's disease is improved. The compound has good development prospect and application value in treatment of Parkinson's disease or other neurodegenerative diseases.

Complexes (e.g., co-crystals) of xanomeline-quercetin, which may be in specific crystalline form, and trospium pamoate salt, which may be in specific crystalline form, as well as pharmaceutical compositions comprising such and methods for their uses, singly or in combination.

The invention provides a method for extracting and purifying flavonoid compounds in sophora flower buds through a solvent-free subcritical water one-pot method, and belongs to the field of green extraction technologies and natural product processing. Firstly, raw material enzyme treatment is carried out, sophora flower buds are put into a sealed stirring reactor; adding an acetic acid buffer solution with the pH value of 4.4-5.0 and the concentration of 0.07-0.15 M, and adding ascorbic acid as an antioxidant; introducing nitrogen to establish an inert atmosphere; adding an enzyme preparation; performing incubation; then carrying out subcritical water extraction to obtain a flavonoid compound crude product; and finally, crystallizing and purifying to obtain a flavonoid compound finished product. According to the method, an organic solvent is not needed, extraction and purification are integrated, rutin or quercetin is selectively produced through simple parameter regulation and control, the production process is green and environmentally friendly, the yield and purity of flavonoid compounds are improved, the processing time is shortened, and the production cost is reduced.

The invention relates to the technical field of anti-cancer drugs, and provides a traditional Chinese medicine multi-component nano drug delivery system as well as a preparation method and application thereof. According to the invention, honokiol (HN) is entrapped by adopting lipid nanoparticles formed by a berberine (BR)-disulfide bond-caprylic capric triglyceride compound, the surface of the lipid nanoparticles is coated with a gelatin layer, and quercetin (QE) is entrapped in the gelatin layer, so that simultaneous delivery of HN, BR and QE and programmed release outside and inside cells are realized. Furthermore, the surface of the gelatin layer is modified with PEG, so that the long circulation of the drug delivery system in blood is improved; furthermore, cRGD is connected to PEG, and the synergistic lung cancer resisting effect of HN, BR and QE is greatly improved through the targeting effect of cRGD. In conclusion, the drug delivery system provided by the invention can give full play to the effect of synergistically treating lung cancer by HN, QE and BR, and has a wide application prospect.

The application belongs to the technical field of medicine, and relates to a compound composition, a preparation method and application, in particular to a compound sodium salicylate composition for treating acute pancreatitis and a preparation method. The compound sodium salicylate composition comprises quercetin, diammonium glycyrrhizinate and sodium salicylate, wherein the mass ratio of quercetin, diammonium glycyrrhizinate and sodium salicylate is 1-5:5-20:50-200. When the compound sodium salicylate composition is an injection, it comprises quercetin, diammonium glycyrrhizinate, sodium salicylate, 1,2-propanediol, sodium bisulfite, dimethyl sulfoxide and 0.9% sodium chloride injection. The volume ratio of 1,2-propanediol and dimethyl sulfoxide in the injection is 14-20% and 0.25-1% respectively; and the mass / volume ratio of sodium bisulfite in the injection is 0.1-0.3%. The compound sodium salicylate composition can significantly reduce amylase, lipase, IL-6 and IL-1beta, and can be used for preparing a medicine for treating pancreatitis.

The invention relates to an application of Quercetin (QUE) or a derivative thereof in a medicine for resisting vocal cord fibrosis and a preparation of the Quercetin or the derivative thereof. The quercetin can significantly inhibit abnormal deposition of extracellular matrix (ECM) after vocal cord injury, improve reduction of hyaluronic acid (HA) and elastic fibers (EF), and reduce overexpression of type I collagen (COL1A1) and fibronectin (FN1). Besides, by regulating PI3K / AKT and MAPK signal channels, the quercetin inhibits proliferation and migration of fibroblasts and promotes apoptosis of the fibroblasts, so that vocal cord fibrosis is effectively relieved. The invention also provides an application of a preparation of the quercetin and the derivative thereof combined or not combined with other anti-fibrosis drugs (such as 5-fluorouracil and dexamethasone) in treatment of vocal cord fibrosis, wherein the dosage forms of the preparation comprise an oral preparation, an injection, a spray or a local gel preparation.

The present disclosure is directed to compositions comprising between 50% and 95% weight per weight (w / w) of acetic acid, between 0.1% and 5% (w / w) of butyric acid or a derivative thereof, and between 0.1% and 5% (w / w) of Quercetin or a derivative thereof. Further, methods of use such as for the treatment and prevention of a medical condition associated with cancer, inflammatory diseases or disorders, metabolic disorders, obesity, diabetes, high blood pressure, vascular diseases, viral infection, and any combination thereof, in a subject in need thereof are also provided.

The invention discloses an anti-inflammatory composition containing mesenchymal stem cells and a preparation method of the anti-inflammatory composition, belongs to the technical field of mesenchymal stem cells, and particularly relates to the anti-inflammatory composition containing the mesenchymal stem cells and the preparation method of the anti-inflammatory composition. The anti-inflammatory composition comprises mesenchymal stem cells, a cell culture solution and a functional additive, the functional additive is prepared from quercetin, tenoside and modified curcumin; the modified curcumin is a curcumin derivative which takes pentaethylene glycol as a connecting arm, one end of the modified curcumin is modified with salicylic acid leaf alcohol ester, and the other end of the modified curcumin is connected with curcumin through an ester bond; the mass ratio of the quercetin to the tenoside is 1: (0.05-0.2), and the mass ratio of the quercetin to the modified curcumin is 1: (0.1-0.4). The anti-inflammatory composition containing the mesenchymal stem cells, disclosed by the invention, can inhibit the expression of a proinflammatory factor by regulating and controlling an inflammation signal channel, so that the inflammation condition of a body is relieved.

The invention belongs to the technical field of membrane separation, and particularly relates to a quercetin-doped reverse osmosis composite membrane, a preparation method thereof and a water purification method. The quercetin-doped reverse osmosis composite membrane comprises a polysulfone microfiltration base membrane and a quercetin-doped polyamide selection layer, the quercetin-doped polyamide selection layer is attached to the surface of at least one side of the polysulfone microfiltration base membrane; the quercetin-doped polyamide selection layer comprises quercetin and a polyamide skeleton, and the quercetin and the polyamide skeleton are connected through an ester bond and / or a hydrogen bond. The quercetin-doped reverse osmosis composite membrane at least meets one of the following conditions: the surface roughness is 121 nm to 199 nm; the water contact angle is 50-60 degrees; under the conditions of 20 bar and 25 DEG C + / -1 DEG C, the retention rate on a 2000 mg.L <-1 > NaCl solution is greater than or equal to 95%; the Zeta potential is-30mV to-60mV when the pH value is equal to 7; the sustained release rate of quercetin is 0.1 [mu] g.cm <-2 >. D <-1 >-10 [mu] g.cm <-2 >. D <-1 >; the killing rate of escherichia coli is greater than or equal to 90%; and the killing rate of staphylococcus aureus is greater than or equal to 90%.

The invention provides a quercetin eutectic composition which is prepared from the following raw materials in percentage by mass: 20-35% of quercetin, 10-75% of a eutectic compound and 10-56% of a crystal inhibitor, and the total amount of all the raw materials is 100%. The co-former is nicotinamide or L-proline, and the crystal inhibitor is povidone K30 or Kollidon VA64. The preparation method comprises the following steps: adding the co-former and the crystal inhibitor into the co-former; the quercetin eutectic composition prepared by the method can effectively inhibit crystal nucleation and growth of drugs in a supersaturated solution, and improve the stability of the active drug supersaturated solution in a solid-liquid interface layer and a bulk solution; the limitation that the solubility advantage of the eutectic crystal cannot be maintained is broken through, and a new thought is provided for research of a high-solubility quercetin eutectic crystal preparation.

The application provides a method for establishing HPLC fingerprint of Changnyle capsule (I), which is characterized in that 16 active components including gastrodin, danshensu, quercetin-3-O-beta-D-glucose-7-O-beta-D-gentiopicroside, 3'-hydroxy puerarin, puerarin, 3'-methoxy puerarin, puerarin apioside, paeoniflorin, daidzin, rosmarinic acid, shikonin, isoquercitrin, ononin, daidzein, salvianolic acid B and calycosin are used as reference substances, HPLC is adopted, methanol-acetonitrile-0.5vol% phosphoric acid aqueous solution is used as a mobile phase, different batches of samples are detected, and finally the fingerprint of Changnyle capsule (I) is obtained. The fingerprint can comprehensively represent the main components in Changnyle capsule (I), thereby being beneficial to the quality control of Changnyle capsule (I).

The application provides an electronic atomization liquid and a preparation method thereof, components of the electronic atomization liquid include nicotine salt, antioxidants and solvents, the antioxidants include tea polyphenol derivatives, quercetin, phytic acid and ascorbic acid palmitate, and the mass ratio of the tea polyphenol derivatives, the quercetin, the phytic acid and the ascorbic acid palmitate in the antioxidants is (3-5):(2-4):(2-4):(1-2). The electronic atomization liquid can inhibit the oxidation reaction of the nicotine salt, reduce the photo-oxidation discoloration of the electronic atomization liquid, significantly improve the color stability of the electronic atomization liquid, and prolong the shelf life of the product.

The invention provides a rehmannia pigment compound as shown in a formula (I), a stereoisomer thereof or pharmaceutically acceptable salt thereof, and particularly relates to the technical field of natural pharmaceutical chemistry and pharmaceutical compounds. The invention aims to solve the problems that the radix rehmanniae pigment is not clear in material basis and lacks a compound with a clear structure and excellent anti-inflammatory activity. The rehmannia pigment compound disclosed by the invention comprises a structure as shown in a formula (I). The invention also discloses a preparation method of the compound and application of the compound in medicines. The compound has a novel chemical structure and remarkable anti-inflammatory activity, release of nitric oxide can be effectively inhibited in a lipopolysaccharide induced macrophage model, the cytotoxicity is far lower than that of a positive control drug quercetin, and the compound shows huge potential as an anti-inflammatory drug lead compound.

The invention discloses a quercetin composite methyl blue light catalyst and a preparation method and application thereof, and relates to the technical field of photocatalyst preparation, and the preparation method comprises the following steps: S1, placing quercetin and methyl blue in a beaker, adding deionized water, then adding H2SO4 and absolute ethyl alcohol, and stirring to obtain a mixed solution; s2, transferring the mixed solution into a hydrothermal reaction kettle with a polytetrafluoroethylene lining for constant-temperature reaction; and S3, after the constant-temperature reaction is finished, cooling to room temperature, washing a reaction product with deionized water, and then drying and grinding the reaction product into powder. According to the photocatalyst disclosed by the invention, a stable compound structure is constructed by utilizing the dihydrogen-bond interaction between hydroxyl of quercetin and sulfo and amino of methyl blue, and the photocatalytic activity is remarkably enhanced. Under the irradiation of visible light, the prepared photocatalyst shows excellent lignite depolymerization performance, and humic acid and fulvic acid rich in hydroxyl and amino can be efficiently generated.

The invention belongs to the technical field of food processing and medicine preparation, and particularly relates to a uric acid reducing composition and a preparation and application thereof. According to the invention, the functional active components capsaicin and quercitrin in hot pepper are found for the first time and both have prevention and improvement effects on hyperuricemia. The two medicines can inhibit activity of purine metabolism key enzyme, promote excretion of uric acid, reduce oxidative stress and inflammatory factor level of a body, delay pathological process of hyperuricemia and protect liver and kidney functions, and do not cause liver and kidney injury and other side effects after long-term use. Moreover, the uric acid reducing effect of cooperative intervention of the capsaicin and the quercitrin, the improvement effect on hyperuricemia and the molecular mechanism of the hyperuricemia are clarified from multiple aspects, and it is proved that the capsaicin and the quercitrin are compounded according to a certain proportion to achieve synergistic interaction. Capsaicin and quercitrin are taken as active ingredients and can be used for developing health care products and medicines with the uric acid reducing effect.

The present invention relates to the use of a composition comprising an effective amount of a combination of fesoterodine and / or a derivative thereof and quercetin and / or a derivative for preventing or treating a bone disorder or maintaining bone health in an individual.

The invention belongs to the technical field of preparation of anti-scar products, and particularly relates to an anti-scar compound, preparation of the anti-scar compound, and a microneedle and a microneedle patch containing the anti-scar compound. The anti-scar compound is prepared from the following raw materials: a compound containing catechol and a compound containing an active oxygen sensitive protecting group; the compound containing catechol is selected from one or more of chlorogenic acid, epigallocatechin gallate and quercetin, and the compound containing catechol is selected from one or more of chlorogenic acid, epigallocatechin gallate and quercetin; the compound containing the active oxygen sensitive protecting group is selected from one or more of 3-aminophenylboronic acid, 4-aminophenylboronic acid, 3-formyl phenylboronic acid and 4-formyl phenylboronic acid. The anti-scar compound has a dynamic borate bond and has good responsiveness to a microenvironment of active oxygen at scars, and the anti-scar compound capable of adjusting a focus microenvironment based on a scar endogenous pathogenic mechanism is introduced into a microneedle formula, so that the microneedle has an obvious anti-scar effect; and the administration period can be obviously shortened and the administration frequency can be reduced by virtue of the micro injection.

The invention discloses a preparation method and application of a quercetin derivative grafted with 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione with a blood sugar reducing function. According to the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound disclosed by the invention, the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound is prepared by linking quercetin-3-O-glucuronide with 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione, the structural formula of the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound is shown as a formula (I), and the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound prepared by the invention has the function of reducing blood sugar and can be used for preparing medicines for treating diabetes mellitus.

The invention discloses a keloid treatment gel material capable of reducing lactic acid generation, and belongs to the technical field of keloid treatment. The material is prepared by the following steps: firstly, carrying out esterification on 9-oxabicyclo [3.3. 1] nonane-2, 6-diol and S-allyl-L-cysteine to obtain an intermediate A, and then carrying out Schiff base reaction on the intermediate A and 5-methoxy heliotropin to obtain an intermediate B containing double bonds; then, copolymerizing with methylacryloylated chitosan and polyethylene glycol diacrylate under photo-initiation to form a cross-linked network structure; finally, active ingredients such as quercetin-3-O-glucuronide and luteolin-3 '-glucuronide are included, and auxiliary materials such as a humectant and a preservative are added, so that the composition is prepared. The gel has a slow release function, can effectively inhibit glycolysis, reduce lactic acid generation, scavenge free radicals and regulate inflammation and fibrosis microenvironment, has good biocompatibility and oxidation response drug release characteristics, and is suitable for prevention and treatment of keloids.